: Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group.
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera / Barbui, T., Vannucchi, A.M., De Stefano, V., Carobbio, A., Ghirardi, A., Carioli, G., Masciulli, A., Rossi, E., Ciceri, F., Bonifacio, M., Iurlo, A., Palandri, F., Benevolo, G., Pane, F., Ricco, A., Carli, G., Caramella, M., Rapezzi, D., Musolino, C., Siragusa, S., et al.. - In: NEJM EVIDENCE. - ISSN 2766-5526. - 2:6(2023), pp. EVIDoa2200335-EVIDoa2200335. [10.1056/EVIDoa2200335]
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
Carobbio, Alessandra;
2023
Abstract
: Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group.
| File | Dimensione | Formato | |
|---|---|---|---|
|
EVIDoa2200335.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
784.94 kB
Formato
Adobe PDF
|
784.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
